• Explore /
  • Poster
  • / Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

Abstract Video & Slides Poster

Authors

null

Robert M. Rifkin

US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO

Robert M. Rifkin , Jason M. Melear , Edward Faber , William I. Bensinger , John M. Burke , Mohit Narang , Don A. Stevens , Kathleen Gray , Yana Lutska , Padma Bobba , Keqin Qi , Ming Qi , Thomas S. Lin , Habte Aragaw Yimer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02951819

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8035)

DOI

10.1200/JCO.2021.39.15_suppl.8035

Abstract #

8035

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: E. Bridget Kim

First Author: Rujul H Parikh

First Author: Saad Z. Usmani

First Author: Shaji Kumar